Natixis Advisors LLC Has $1.30 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Natixis Advisors LLC boosted its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 36.2% in the third quarter, Holdings Channel reports. The fund owned 28,144 shares of the biotechnology company’s stock after acquiring an additional 7,484 shares during the period. Natixis Advisors LLC’s holdings in Corcept Therapeutics were worth $1,303,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in Corcept Therapeutics during the third quarter worth $25,000. Park Place Capital Corp acquired a new position in Corcept Therapeutics in the second quarter valued at about $32,000. Atwood & Palmer Inc. bought a new stake in Corcept Therapeutics during the second quarter worth about $35,000. Kathleen S. Wright Associates Inc. acquired a new stake in shares of Corcept Therapeutics during the third quarter worth approximately $36,000. Finally, Blue Trust Inc. raised its stake in shares of Corcept Therapeutics by 125.4% in the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,962 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CORT has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a report on Thursday, October 31st. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Piper Sandler raised their price target on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. Finally, Truist Financial boosted their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $65.25.

Insider Buying and Selling

In other news, insider William Guyer sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the transaction, the insider now directly owns 6,039 shares of the company’s stock, valued at approximately $213,176.70. This trade represents a 62.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the sale, the insider now owns 22,772 shares of the company’s stock, valued at approximately $1,053,888.16. The trade was a 32.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,611 shares of company stock valued at $1,563,548. Company insiders own 20.50% of the company’s stock.

Corcept Therapeutics Trading Down 0.8 %

CORT opened at $58.58 on Wednesday. The firm’s fifty day simple moving average is $48.82 and its 200 day simple moving average is $38.29. The stock has a market capitalization of $6.14 billion, a P/E ratio of 46.49 and a beta of 0.45. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $61.66.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.14. The firm had revenue of $182.55 million for the quarter, compared to analyst estimates of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company’s revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.28 EPS. As a group, research analysts anticipate that Corcept Therapeutics Incorporated will post 1.35 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.